ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation

Conference9MW2821Positive

AI Analysis

Summary

Mabwell will present clinical study results for 9MW2821, a Nectin-4-targeting antibody-drug conjugate, for triple-negative breast cancer at ESMO 2026 in an oral presentation.

Clinical Trial Data

Importance:5/10

Sentiment:

0.50

ADCNectin-4triple-negative breast cancerclinical dataESMO 2026

Related Companies

$IPIX $INBP

Read the original article

Published by PR Newswire Biotech on July 21, 2026 3:50 AM

Read Original